ERBB2 and breast carcinoma: Extensive in vitro and in vivo studies have unequivocally revealed the significant growth-inhibitory effects of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2-0 and HR+/HER2-low breast cancer cell subtypes.